About this podcast:
Recorded at the 2025 DPHARM conference, this state of the union panel convenes site, technology and pharma to discuss: 

• Different models and the pros and cons of the deployment models
• What makes a great patient matching solution
• Predicting what the future growth of this segment looks like
• The role of AI in this space

About this podcast: 
Recorded at the 2025 IO360º Summit, this podcast addresses how Project Optimus is reshaping dose selection from maximum tolerated dose to a balance of efficacy and safety. More specifically, this panel addresses FDA objectives for multi-dose selection, alternative dose-selection strategies with imaging, biomarkers and tumor burden analysis, the higher costs and longer timelines, and financial impacts for early-phase oncology companies. 

For more information, go to IO360summit.com.

About this podcast: 
Recorded at the 2025 CRAACO meeting, UNC Lineberger’s Comprehensive Cancer Center shares  an initiative to allow local HCPs to still provide clinical care to patients but decentralized research elements to the university system, following the FDA’s change in guidance on Form FDA 1572, which stopped requiring local healthcare professionals (HCPs) involved in DCTs to be listed if they’re only performing standard-of-care. 


Dr J Kaitlin Morrison talks about the process from an initial pilot of two sites to more than 23 today, providing cancer patients across the state the opportunity to access clinical trials. Specifically:

• How they are managing relationships with sites
• How they’re monitoring research elements
• Goals, next steps and thoughts for industry sponsors

About this podcast:
This podcast, recorded at the 2025 Patients as Partners Europe meeting, addresses how Novo Nordisk is consolidating patient insights to ensure greater knowledge-sharing, data integrity and traceability, addressing the unmet needs of patients, aligning product outcomes with patient expectations, and more. 

For more information, go to theconferenceforum.org.

In this podcast, Kate Woda, Conference Director of the Patients as Partners in Clinical Research conference discusses what attendees can expect at the 13th annual event, including key topic areas, session highlights, presenting companies and more. For more information about the upcoming event, full agenda and speakers, visit patientsaspartnersconference.com.

In this podcast, featuring a panel discussion from the 2025 Chief Medical Officer Summit 360°, CMOs with recent M&A and partnership experience share those experiences as well as how CMOs of other small to midsize emerging biotech companies can support the conversations and operations that take place throughout the process of business development. Specifically:

• Different kinds of BD deals to be aware of
• How the CMO fits into various phases of transactions
• Appreciating how different c-suite colleagues and direct reports experience these transactions
• The different pharma teams CMOs will interact with
• What happens after the acquisition

To learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss conjugation and bioconjugation approaches to make ASOs and small molecules more tolerable while improving targeting. Technologies discussed include ADCs, PDCs, SMDCs, VDCs, RDCs and AOCs. Specifically they address:

• Biological and chemical challenges for these therapies
• Building out scalable manufacturing and a regulatory strategy
• Hurdles to overcome to get products to market

To learn more about the PODD Conference, please visit Drug-Delivery.org.

This podcast features a panel discussion from the 2025 Chief Medical Officer Summit 360° about how to strategically approach hiring FTEs, insourcing, outsourcing and contracting to be appropriately prepared for the different stages of a biotech companies development from preclinical to early stage to late stage trials to commercialization. Specifically:

• Balancing the mix of hires and outsourcing
• Hiring for skillsets to enable efficiency without overhiring
• Reactive vs proactive hiring
• Building in a stage appropriate way but also hiring in time for later stages

To learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.

While lipid nanoparticles are the most clinically advanced drug delivery system for nucleic acid therapeutics, they are only one tool in a toolbox of potential delivery vehicles.

In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss additional tools, including polymeric nanoparticles, protein-based nanoparticles and extracellular vesicles with a focus on:

• Where LNPs potentially fall short
• Where different tools can enable therapeutic delivery
• Challenges to achieving meaningful clinical impact for these different vehicles
• Building out a portfolio of delivery vehicles

To learn more about the PODD Conference, please visit Drug-Delivery.org.

About this podcast: 
This podcast comes from the DPHARM 2025 meeting. Pfizer details how they jointly co-designed and implemented an EDC/CDMS platform that’s fit for purpose, and analysis data set. This session focuses on:

• Engaging all stakeholders in designing the platform
• The evolution of the platform focus: the transition from the majority of data coming from EDC to 3/4 of the data from third party sources
• Impact of the advanced data analysis capabilities for risk management
• Review of impact on initial studies now using the platform 

For more information, go to DPHARMconference.com.